Abrar A. Qureshi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Abrar A. Qureshi has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
Jiali Han
Department of Dermatology, Brigham and Women’s Hospital and Harvard Medical School, Boston, USA
13 shared publicationsTricia Li
Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, USA
5 shared publicationsWenqing Li
Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA
4 shared publicationsShaowei Wu
Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts
3 shared publicationsWen-Qing Li
Department of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
3 shared publicationsAndrew C. Walls
2 shared publications
Latest Publications
- 1 August 2016
- Vol. 15 (8) , 1011-6
Shedding Light on the "Hidden Psoriasis": A Pilot Study of the Inverse Psoriasis Burden of Disease (IPBOD) Questionnaire.
While burden of disease (BOD) data exists for plaque psoriasis, and to a lesser extent other phenotypes of psoriasis, there is no published data on the impact of inverse (intertriginous) psoriasis. We sought to assess the overall BOD among patients with inverse psoriasis (IP). We introduce the Inverse Psoriasis Burden of Disease (IPBOD) questionnaire and compare it to the Dermatology Life Quality Index (DLQI). In this cross-sectional pilot study, we administered the IPBOD and the DLQI to 16 patients. We present the initial psychometric properties of the IPBOD survey. We used Spearman's correlation coefficients to compare the two questionnaires on overall performance and in specific domains. Our cohort had an average age of 55.6 (SD 16.6) years, was predominantly female (68.8%), and white (87.5%). 87.5% of patients had a second psoriasis subtype. A majority of patients reported some effect of IP on pain (n=14, 87.5%). Thirteen (81.3%) patients reported some effect on depressed mood or anxiety/worry. Overall, the largest effect was on body self-image (93.8% reporting an effect). The average DLQI score was 8.5/30, higher than average DLQI scores reported in patients with plaque psoriasis or psoriatic arthritis. Average IPBOD score was 4.9/10. The reliability of IPBOD was good (overall Cronbach's alpha = 0.89, individual items' range 0.88 - 0.91). Correlations between IPBOD and DLQI were: overall (Spearman's P=0.650, P=0.006), symptoms (P=0.462, P=0.072), daily activities (P=0.507, P=0.045), leisure (P=0.633, P=0.008), interpersonal function (P=0.728, P=0.001), and work and school (P=0.427, P=0.100). IP has a profound impact on patients' lives and the results of this pilot study suggest that the IPBOD questionnaire may be a useful disease-specific tool for measuring the BOD of IP. J Drugs Dermatol. 2016;15(8):1011-1016.
- 1 August 2016
- Vol. 15 (8) , 1011-6
Shedding Light on the "Hidden Psoriasis": A Pilot Study of the Inverse Psoriasis Burden of Disease (IPBOD) Questionnaire.
While burden of disease (BOD) data exists for plaque psoriasis, and to a lesser extent other phenotypes of psoriasis, there is no published data on the impact of inverse (intertriginous) psoriasis. We sought to assess the overall BOD among patients with inverse psoriasis (IP). We introduce the Inverse Psoriasis Burden of Disease (IPBOD) questionnaire and compare it to the Dermatology Life Quality Index (DLQI). In this cross-sectional pilot study, we administered the IPBOD and the DLQI to 16 patients. We present the initial psychometric properties of the IPBOD survey. We used Spearman's correlation coefficients to compare the two questionnaires on overall performance and in specific domains. Our cohort had an average age of 55.6 (SD 16.6) years, was predominantly female (68.8%), and white (87.5%). 87.5% of patients had a second psoriasis subtype. A majority of patients reported some effect of IP on pain (n=14, 87.5%). Thirteen (81.3%) patients reported some effect on depressed mood or anxiety/worry. Overall, the largest effect was on body self-image (93.8% reporting an effect). The average DLQI score was 8.5/30, higher than average DLQI scores reported in patients with plaque psoriasis or psoriatic arthritis. Average IPBOD score was 4.9/10. The reliability of IPBOD was good (overall Cronbach's alpha = 0.89, individual items' range 0.88 - 0.91). Correlations between IPBOD and DLQI were: overall (Spearman's P=0.650, P=0.006), symptoms (P=0.462, P=0.072), daily activities (P=0.507, P=0.045), leisure (P=0.633, P=0.008), interpersonal function (P=0.728, P=0.001), and work and school (P=0.427, P=0.100). IP has a profound impact on patients' lives and the results of this pilot study suggest that the IPBOD questionnaire may be a useful disease-specific tool for measuring the BOD of IP. J Drugs Dermatol. 2016;15(8):1011-1016.
- 1 June 2015
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 42 (6) , 1032-1033
A Comprehensive Assessment Tool for Psoriasis — An Unmet Need: Report from the GRAPPA 2014 Annual Meeting
Psoriasis is a chronic inflammatory skin condition that has several distinct clinical subtypes, the most common of which is plaque psoriasis. Other non-plaque subtypes, however, including scalp, nail, inverse, and palmoplantar, have been demonstrated to be more common than previously believed, are associated with a significant burden of disease, and are likely underdiagnosed and undertreated. Understanding the effects of these non-plaque psoriasis subtypes can be challenging given that the gold standard psoriasis tool, the Psoriasis Area and Severity Index, is mostly directed at plaque psoriasis. Therefore, a tool that can more comprehensively assess the psoriasis patient represents an unmet need in dermatology. Herein we discuss the concept of an ideal tool that addresses both plaque and non-plaque subtypes, with equal contribution from physician and patient, as discussed at the 2014 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
- 1 June 2015
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 42 (6) , 1032-1033
A Comprehensive Assessment Tool for Psoriasis — An Unmet Need: Report from the GRAPPA 2014 Annual Meeting
Psoriasis is a chronic inflammatory skin condition that has several distinct clinical subtypes, the most common of which is plaque psoriasis. Other non-plaque subtypes, however, including scalp, nail, inverse, and palmoplantar, have been demonstrated to be more common than previously believed, are associated with a significant burden of disease, and are likely underdiagnosed and undertreated. Understanding the effects of these non-plaque psoriasis subtypes can be challenging given that the gold standard psoriasis tool, the Psoriasis Area and Severity Index, is mostly directed at plaque psoriasis. Therefore, a tool that can more comprehensively assess the psoriasis patient represents an unmet need in dermatology. Herein we discuss the concept of an ideal tool that addresses both plaque and non-plaque subtypes, with equal contribution from physician and patient, as discussed at the 2014 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
- 28 May 2014
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 306 (6) , 555-560
Invasive cutaneous squamous cell carcinoma incidence in US health care workers
Little data on cutaneous squamous cell carcinoma (SCC) epidemiology within the United States are currently available. Prior studies have focused on populations outside of the United States or been limited to regions within the US. In this study, prospective data were collected via biennial questionnaires from a total of 261,609 participants, which included women in the Nurses’ Health Study (NHS, 1976–2008) and Nurses’ Health Study II (NHS II, 1989–2009), and men in the Health Professionals Follow-Up Study (HPFS, 1986–2008). History of physician-diagnosed invasive SCC was confirmed by pathology record review. Over the entire follow-up period for each cohort, there were 1,265 invasive SCC cases per 100,000 persons in the NHS cohort, 389 cases per 100,000 persons in NHS II, and 2,154 cases per 100,000 persons in HPFS. An 18-year follow-up of participants in these cohorts revealed increasing invasive SCC incidence rates over time, with rates for men being consistently higher than those for women. In women, a larger proportion of invasive SCC lesions occurred on the lower extremities as compared to men (21 % in NHS vs. 6 % in HPFS, p < 0.0001; 14 % in NHS II vs. 6 % in HPFS, p < 0.0001), while in men, a larger proportion occurred on the head/neck (43 % in NHS vs. 60 % in HPFS, p < 0.0001; 48 % in NHS II vs. 60 % in HPFS, p < 0.0001). In summary, invasive SCC incidence rates among US men have been greater than those for women with distinct sites of common occurrence between men and women.
- 28 May 2014
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 306 (6) , 555-560
Invasive cutaneous squamous cell carcinoma incidence in US health care workers
Little data on cutaneous squamous cell carcinoma (SCC) epidemiology within the United States are currently available. Prior studies have focused on populations outside of the United States or been limited to regions within the US. In this study, prospective data were collected via biennial questionnaires from a total of 261,609 participants, which included women in the Nurses’ Health Study (NHS, 1976–2008) and Nurses’ Health Study II (NHS II, 1989–2009), and men in the Health Professionals Follow-Up Study (HPFS, 1986–2008). History of physician-diagnosed invasive SCC was confirmed by pathology record review. Over the entire follow-up period for each cohort, there were 1,265 invasive SCC cases per 100,000 persons in the NHS cohort, 389 cases per 100,000 persons in NHS II, and 2,154 cases per 100,000 persons in HPFS. An 18-year follow-up of participants in these cohorts revealed increasing invasive SCC incidence rates over time, with rates for men being consistently higher than those for women. In women, a larger proportion of invasive SCC lesions occurred on the lower extremities as compared to men (21 % in NHS vs. 6 % in HPFS, p < 0.0001; 14 % in NHS II vs. 6 % in HPFS, p < 0.0001), while in men, a larger proportion occurred on the head/neck (43 % in NHS vs. 60 % in HPFS, p < 0.0001; 48 % in NHS II vs. 60 % in HPFS, p < 0.0001). In summary, invasive SCC incidence rates among US men have been greater than those for women with distinct sites of common occurrence between men and women.
- 15 April 2014
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 170 (4) , 994-995
Psoriatic arthritis screening tools: study design and methodological challenges
- 15 April 2014
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 170 (4) , 994-995
Psoriatic arthritis screening tools: study design and methodological challenges
- Open Access
- 4 March 2014
- Published by Springer Nature in British Journal of Cancer
- Vol. 110 (7) , 1855-1861
Cumulative ultraviolet radiation flux in adulthood and risk of incident skin cancers in women
Background: Solar ultraviolet (UV) exposure estimated based on residential history has been used as a sun exposure indicator in previous case–control and descriptive studies. However, the associations of cumulative UV exposure based on residential history with different skin cancers, including melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC), have not been evaluated simultaneously in prospective studies. Methods: We conducted a cohort study among 108 578 women in the Nurses’ Health Study (1976–2006) to evaluate the relative risks of skin cancers with cumulative UV flux based on residential history in adulthood. Results: Risk of SCC and BCC was significantly lower for women in lower quintiles vs the highest quintile of cumulative UV flux (both P for trend vs the highest quintile of cumulative UV flux in lag analyses with 2–10 years between exposure and outcome. The multivariable-adjusted hazard ratios per 200 × 10−4 Robertson–Berger units increase in cumulative UV flux were 0.979 (95% confidence interval (CI): 0.933, 1.028) for melanoma, 1.072 (95% CI: 1.041, 1.103) for SCC, and 1.043 (95% CI: 1.034, 1.052) for BCC. Conclusions: Associations with cumulative UV exposure in adulthood among women differed for melanoma, SCC, and BCC, suggesting a potential variable role of UV radiation in adulthood in the carcinogenesis of the three major skin cancers.
- 4 March 2014
- Published by Springer Nature in British Journal of Cancer
- Vol. 110 (7) , 1855-1861
Open AccessCumulative ultraviolet radiation flux in adulthood and risk of incident skin cancers in women
Background: Solar ultraviolet (UV) exposure estimated based on residential history has been used as a sun exposure indicator in previous case–control and descriptive studies. However, the associations of cumulative UV exposure based on residential history with different skin cancers, including melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC), have not been evaluated simultaneously in prospective studies. Methods: We conducted a cohort study among 108 578 women in the Nurses’ Health Study (1976–2006) to evaluate the relative risks of skin cancers with cumulative UV flux based on residential history in adulthood. Results: Risk of SCC and BCC was significantly lower for women in lower quintiles vs the highest quintile of cumulative UV flux (both P for trend vs the highest quintile of cumulative UV flux in lag analyses with 2–10 years between exposure and outcome. The multivariable-adjusted hazard ratios per 200 × 10−4 Robertson–Berger units increase in cumulative UV flux were 0.979 (95% confidence interval (CI): 0.933, 1.028) for melanoma, 1.072 (95% CI: 1.041, 1.103) for SCC, and 1.043 (95% CI: 1.034, 1.052) for BCC. Conclusions: Associations with cumulative UV exposure in adulthood among women differed for melanoma, SCC, and BCC, suggesting a potential variable role of UV radiation in adulthood in the carcinogenesis of the three major skin cancers.
- Open Access
- 18 December 2013
- Published by Wiley in Arthritis & Rheumatology
- Vol. 66 (2) , 304-310
Hypercholesterolemia and Risk of Incident Psoriasis and Psoriatic Arthritis in US Women
Objective: Psoriasis is a systemic inflammatory disorder associated with an increased risk of cardiovascular disease. Hypercholesterolemia is a major risk factor for cardiovascular disease, and patients with psoriasis or psoriatic arthritis (PsA) have been shown to have elevated cholesterol levels. However, it is not known whether hypercholesterolemia is associated with an increased risk of psoriasis or psoriasis with PsA. We undertook this study to determine whether a history of hypercholesterolemia is associated with the risk of developing incident psoriasis and psoriasis with PsA in a cohort of US women.Methods: We included a total of 95,540 participants from the Nurses' Health Study II (1991–2005). Information on personal history of physician‐diagnosed hypercholesterolemia and related medication use was collected during the followup period. Clinician‐diagnosed psoriasis and psoriasis with PsA were ascertained and confirmed using supplementary questionnaires. Hazard ratios (HRs) were calculated with 95% confidence intervals (95% CIs).Results: During 1,320,765 person‐years of followup, we documented 646 participants with incident psoriasis, 165 of whom had concomitant PsA. Hypercholesterolemia was associated with elevated risks of incident psoriasis (HR 1.25 [95% CI 1.04–1.50]) and psoriasis with PsA (HR 1.58 [95% CI 1.13–2.23]) in multivariate‐adjusted models. Participants with hypercholesterolemia lasting for ≥7 years were at a higher risk of developing psoriasis (HR 1.29 [95% CI 1.03–1.61]) (P for trend = 0.0002) and psoriasis with PsA (HR 1.68 [95% CI 1.12–2.52]) (P for trend = 0.002). These associations persisted among participants who never took cholesterol‐lowering medications. There was no association between cholesterol‐lowering drugs and risk of psoriasis or psoriasis with PsA.Conclusion: Our study provides evidence that hypercholesterolemia, a well‐known cardiovascular risk factor, is also associated with an elevated risk of psoriasis and psoriasis with PsA.
- 18 December 2013
- Published by Wiley in Arthritis & Rheumatology
- Vol. 66 (2) , 304-310
Open AccessHypercholesterolemia and Risk of Incident Psoriasis and Psoriatic Arthritis in US Women
Objective: Psoriasis is a systemic inflammatory disorder associated with an increased risk of cardiovascular disease. Hypercholesterolemia is a major risk factor for cardiovascular disease, and patients with psoriasis or psoriatic arthritis (PsA) have been shown to have elevated cholesterol levels. However, it is not known whether hypercholesterolemia is associated with an increased risk of psoriasis or psoriasis with PsA. We undertook this study to determine whether a history of hypercholesterolemia is associated with the risk of developing incident psoriasis and psoriasis with PsA in a cohort of US women.Methods: We included a total of 95,540 participants from the Nurses' Health Study II (1991–2005). Information on personal history of physician‐diagnosed hypercholesterolemia and related medication use was collected during the followup period. Clinician‐diagnosed psoriasis and psoriasis with PsA were ascertained and confirmed using supplementary questionnaires. Hazard ratios (HRs) were calculated with 95% confidence intervals (95% CIs).Results: During 1,320,765 person‐years of followup, we documented 646 participants with incident psoriasis, 165 of whom had concomitant PsA. Hypercholesterolemia was associated with elevated risks of incident psoriasis (HR 1.25 [95% CI 1.04–1.50]) and psoriasis with PsA (HR 1.58 [95% CI 1.13–2.23]) in multivariate‐adjusted models. Participants with hypercholesterolemia lasting for ≥7 years were at a higher risk of developing psoriasis (HR 1.29 [95% CI 1.03–1.61]) (P for trend = 0.0002) and psoriasis with PsA (HR 1.68 [95% CI 1.12–2.52]) (P for trend = 0.002). These associations persisted among participants who never took cholesterol‐lowering medications. There was no association between cholesterol‐lowering drugs and risk of psoriasis or psoriasis with PsA.Conclusion: Our study provides evidence that hypercholesterolemia, a well‐known cardiovascular risk factor, is also associated with an elevated risk of psoriasis and psoriasis with PsA.
- Open Access
- 25 October 2013
- Published by Springer Nature in Cancer Causes & Control
- Vol. 25 (1) , 125-132
CXCR4 pathway associated with family history of melanoma
Purpose Genetic predisposition plays a major role in the etiology of melanoma, but known genetic markers only account for a limited fraction of family-history-associated melanoma cases. Expression microarrays have offered the opportunity to identify further genomic profiles correlated with family history of melanoma. We aimed to distinguish mRNA expression signatures between melanoma cases with and without a family history of melanoma. Methods Based on the Nurses’ Health Study, family history was defined as having one or more first-degree family members diagnosed with melanoma. Melanoma diagnosis was confirmed by reviewing pathology reports, and tumor blocks were collected by mail from across the USA. Genomic interrogation was accomplished through evaluating expression profiling of formalin-fixed paraffin-embedded tissues from 78 primary cutaneous invasive melanoma cases, on either a 6K or whole-genome (24K) Illumina gene chip. Gene set enrichment analysis was performed for each batch to determine the differentially enriched pathways and key contributing genes. Results The CXC chemokine receptor 4 (CXCR4) pathway was consistently up-regulated within cases of familial melanoma in both platforms. Leading edge analysis showed four genes from the CXCR4 pathway, including MAPK1, PLCG1, CRK, and PTK2, were among the core members that contributed to the enrichment of this pathway. There was no association between the enrichment of CXCR4 pathway and NRAS, BRAF mutation, or Breslow thickness of the primary melanoma cases. Conclusions We found that the CXCR4 pathway might constitute a novel susceptibility pathway associated with family history of melanoma in first-degree relatives.
- 25 October 2013
- Published by Springer Nature in Cancer Causes & Control
- Vol. 25 (1) , 125-132
Open AccessCXCR4 pathway associated with family history of melanoma
Purpose Genetic predisposition plays a major role in the etiology of melanoma, but known genetic markers only account for a limited fraction of family-history-associated melanoma cases. Expression microarrays have offered the opportunity to identify further genomic profiles correlated with family history of melanoma. We aimed to distinguish mRNA expression signatures between melanoma cases with and without a family history of melanoma. Methods Based on the Nurses’ Health Study, family history was defined as having one or more first-degree family members diagnosed with melanoma. Melanoma diagnosis was confirmed by reviewing pathology reports, and tumor blocks were collected by mail from across the USA. Genomic interrogation was accomplished through evaluating expression profiling of formalin-fixed paraffin-embedded tissues from 78 primary cutaneous invasive melanoma cases, on either a 6K or whole-genome (24K) Illumina gene chip. Gene set enrichment analysis was performed for each batch to determine the differentially enriched pathways and key contributing genes. Results The CXC chemokine receptor 4 (CXCR4) pathway was consistently up-regulated within cases of familial melanoma in both platforms. Leading edge analysis showed four genes from the CXCR4 pathway, including MAPK1, PLCG1, CRK, and PTK2, were among the core members that contributed to the enrichment of this pathway. There was no association between the enrichment of CXCR4 pathway and NRAS, BRAF mutation, or Breslow thickness of the primary melanoma cases. Conclusions We found that the CXCR4 pathway might constitute a novel susceptibility pathway associated with family history of melanoma in first-degree relatives.
- Open Access
- 1 September 2013
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 40 (9) , 1623
Screening Instruments for Psoriatic Arthritis
- 1 September 2013
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 40 (9) , 1623
Open AccessScreening Instruments for Psoriatic Arthritis
- Open Access
- 4 July 2013
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 178 (6) , 890-897
Basal-Cell Carcinoma Incidence and Associated Risk Factors in US Women and Men
There is a paucity of data on basal-cell carcinoma (BCC) in the United States, since most national registries do not collect information on BCC. We evaluated BCC incidence trends and associated risk factors for BCC in 140,171 participants from a US female cohort, the Nurses' Health Study (1986–2006), and a US male cohort, the Health Professionals' Follow-up Study (1988–2006). Age-adjusted BCC incidence rates increased from 519 cases per 100,000 person-years to 1,019 cases per 100,000 person years for women and increased from 606 cases per 100,000 person-years to 1,488 cases per 100,000 person-years for men during the follow-up period. Cox proportional hazards analysis identified the following phenotypic risk factors for BCC in both cohorts: family history of melanoma, blond or red hair colors, higher number of extremity moles, higher susceptibility to sunburn as a child/adolescent, and higher lifetime number of severe/blistering sunburns. The multivariate-adjusted risk ratio for the highest quintile of cumulative midrange ultraviolet B flux exposure versus the lowest quintile was 3.18 (95% confidence interval: 2.70, 3.76) in women and 1.90 (95% confidence interval: 1.57, 2.29) in men. BCC incidence was generally higher in men than in women, and BCC risk was strongly associated with several phenotypic and exposure factors, including midrange ultraviolet B radiation, in our study populations.
- 4 July 2013
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 178 (6) , 890-897
Open AccessBasal-Cell Carcinoma Incidence and Associated Risk Factors in US Women and Men
There is a paucity of data on basal-cell carcinoma (BCC) in the United States, since most national registries do not collect information on BCC. We evaluated BCC incidence trends and associated risk factors for BCC in 140,171 participants from a US female cohort, the Nurses' Health Study (1986–2006), and a US male cohort, the Health Professionals' Follow-up Study (1988–2006). Age-adjusted BCC incidence rates increased from 519 cases per 100,000 person-years to 1,019 cases per 100,000 person years for women and increased from 606 cases per 100,000 person-years to 1,488 cases per 100,000 person-years for men during the follow-up period. Cox proportional hazards analysis identified the following phenotypic risk factors for BCC in both cohorts: family history of melanoma, blond or red hair colors, higher number of extremity moles, higher susceptibility to sunburn as a child/adolescent, and higher lifetime number of severe/blistering sunburns. The multivariate-adjusted risk ratio for the highest quintile of cumulative midrange ultraviolet B flux exposure versus the lowest quintile was 3.18 (95% confidence interval: 2.70, 3.76) in women and 1.90 (95% confidence interval: 1.57, 2.29) in men. BCC incidence was generally higher in men than in women, and BCC risk was strongly associated with several phenotypic and exposure factors, including midrange ultraviolet B radiation, in our study populations.
- 1 July 2013
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 72 (7) , 1200-1205
Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women
Objective Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), shares clinical and immunological features with psoriasis. Genome-wide association studies have found common susceptibility genes. However, epidemiologic data evaluating the association between psoriasis, psoriatic arthritis and risk of IBD are sparse. We aimed to evaluate the association between psoriasis, psoriatic arthritis and incident CD and UC among women in the USA. Methods 174 476 women were enrolled in the Nurses’ Health Study (NHS) (1996–2008) and NHS II (1991–2007). Lifetime history of physician-diagnosed psoriasis and psoriatic arthritis was confirmed by supplementary questionnaires. Information on CD and UC was obtained by self-reported questionnaires and confirmed by medical record review. Results We documented 188 incident cases of CD and 240 incident cases of UC during follow-up. Psoriasis was associated with a significantly increased risk of subsequent CD with a multivariate-adjusted relative risk (RR) of 4.00 (95% CI 1.72 to 9.27) for NHS and 3.76 (1.82 to 7.74) for NHS II. By contrast, we did not observe a significant increase in risk of UC associated with psoriasis. In a pooled analysis of both cohorts, women with psoriasis experienced a significantly increased risk of CD (RR, 3.86, 95% CI 2.23 to 6.67), but not UC (RR, 1.17, 95% CI 0.41 to 3.36). The risk of CD was especially pronounced among psoriatics with concomitant psoriatic arthritis (RR, 6.43, 95% CI 2.04 to 20.32). Conclusions Psoriasis with concomitant psoriatic arthritis is associated with an increased risk of incident CD.
- 1 July 2013
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 72 (7) , 1200-1205
Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women
Objective Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), shares clinical and immunological features with psoriasis. Genome-wide association studies have found common susceptibility genes. However, epidemiologic data evaluating the association between psoriasis, psoriatic arthritis and risk of IBD are sparse. We aimed to evaluate the association between psoriasis, psoriatic arthritis and incident CD and UC among women in the USA. Methods 174 476 women were enrolled in the Nurses’ Health Study (NHS) (1996–2008) and NHS II (1991–2007). Lifetime history of physician-diagnosed psoriasis and psoriatic arthritis was confirmed by supplementary questionnaires. Information on CD and UC was obtained by self-reported questionnaires and confirmed by medical record review. Results We documented 188 incident cases of CD and 240 incident cases of UC during follow-up. Psoriasis was associated with a significantly increased risk of subsequent CD with a multivariate-adjusted relative risk (RR) of 4.00 (95% CI 1.72 to 9.27) for NHS and 3.76 (1.82 to 7.74) for NHS II. By contrast, we did not observe a significant increase in risk of UC associated with psoriasis. In a pooled analysis of both cohorts, women with psoriasis experienced a significantly increased risk of CD (RR, 3.86, 95% CI 2.23 to 6.67), but not UC (RR, 1.17, 95% CI 0.41 to 3.36). The risk of CD was especially pronounced among psoriatics with concomitant psoriatic arthritis (RR, 6.43, 95% CI 2.04 to 20.32). Conclusions Psoriasis with concomitant psoriatic arthritis is associated with an increased risk of incident CD.